Bausch + Lomb (BLCO) Could Be 59% Undervalued On EyeGility Launch
Bausch + Lomb (BLCO) has drawn fresh attention after launching its EyeGility Inserter in the U.S., a preloaded intraocular lens delivery system for its enVista Aspire and upcoming Envy cataract lenses.
See our latest analysis for Bausch + Lomb.
Despite a 1-day share price return that declined 3.27% to around US$16.26 following the EyeGility news, Bausch + Lomb’s 30-day share price return of 9.42% and 1-year total shareholder return of 16.98% suggest improving momentum, even as the 3-year total shareholder return is still down 20.57%.
If you like the direction Bausch + Lomb is taking with AI in eye care, it might be worth broadening your research to other healthcare-focused AI opportunities through the Simply Wall St screener for 39 healthcare AI stocks
After the recent EyeGility driven bump and pullback, the real puzzle for Bausch + Lomb now is whether that 57% discount to estimated intrinsic value still points to meaningful upside, or if the easy gains have already been taken.
Most Popular Narrative: 58.6% Undervalued
According to the most followed narrative on Bausch + Lomb, a fair value of about $39.23 compares to the recent $16.26 close, framing the stock as deeply discounted on that view.
For more than a week following the company’s Annual General Meeting (AGM), shareholders have been left without a single published result, filing, press release, or confirmation of what occurred inside the meeting. This absence of disclosure is not normal, not industry standard, and not aligned with the obligations of a publicly traded company.
This narrative, set out by retail contributor CG86, relies on a detailed set of revenue, margin and future profit assumptions that are in clear tension with today’s ongoing losses and governance questions. The valuation depends on those forecasts holding together.
Result: Fair Value of $39.23 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear risks to this Bausch + Lomb undervaluation story, including ongoing net losses and the governance concerns raised around AGM disclosure.
Find out about the key risks to this Bausch + Lomb narrative.
Next Steps
If this Bausch + Lomb story feels mixed to you, that is the point. Consider acting while sentiment is unsettled and weigh the 3 key rewards
Looking for more investment ideas beyond Bausch + Lomb?
If you are weighing what to do next after reviewing Bausch + Lomb, consider exploring a wider range of stocks that may be more closely aligned with your objectives.
- Scan for value driven opportunities by checking companies on the Simply Wall St screener that appear cheap on fundamentals through the 47 high quality undervalued stocks.
- Strengthen your defense by focusing on businesses with robust finances and consistent metrics using the Simply Wall St solid balance sheet and fundamentals stocks screener (47 results).
- Get ahead of the crowd by reviewing a Simply Wall St screener containing 20 high quality undiscovered gems that could otherwise stay off your radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com